Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements.
Guinn
Barbara
B
Greiner
Jochen
J
Schmitt
Michael
M
Mills
Ken I
KI
D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics* / Q000276:immunology; D019556:COS Cells; D002522:Chlorocebus aethiops; D018572:Disease-Free Survival; D000939:Epitopes / Q000235:genetics* / Q000276:immunology; D005260:Female; D015973:Gene Expression Regulation, Leukemic / Q000235:genetics / Q000276:immunology; D018922:HL-60 Cells; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D020014:K562 Cells; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000276:immunology / Q000473:pathology / Q000628:therapy; D008297:Male; D010455:Peptides / Q000235:genetics* / Q000276:immunology; D011379:Prognosis; D012334:RNA, Neoplasm / Q000235:genetics / Q000276:immunology; D015996:Survival Rate
D000951:Antigens, Neoplasm; D000939:Epitopes; D010455:Peptides; D012334:RNA, Neoplasm